Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | CKS1B | P61024 | 1/20 | 0.32 |
| ▸ | SKP1 | P63208 | 1/20 | 0.32 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | SPR | P35270 | 1/20 | 0.32 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5108774 | 1.00 | ELANE (0.36) | ELANEHSD17B10MEN1KMT2AGRM2 | |
| SCHEMBL30591259 | 0.90 | ELANE (0.36) | ELANEMEN1KMT2AGRM2HSD11B1 | |
| SCHEMBL30591210 | 0.90 | ELANE (0.36) | ELANEMEN1KMT2AGRM2HSD11B1 | |
| SCHEMBL25432290 | 0.88 | PTPN1 (0.38) | ELANEMEN1KMT2AGRM2NR1H2 | |
| SCHEMBL27379993 | 0.88 | PTPN1 (0.38) | ELANEMEN1KMT2AGRM2NR1H2 | |
| SCHEMBL24894252 | 0.84 | KMT2A (0.37) | ELANEMEN1KMT2AGRM2TP53 | |
| SCHEMBL24069357 | 0.84 | ELANE (0.38) | ELANEMEN1KMT2AGRM2HSD11B1 | |
| SCHEMBL7163168 | 0.84 | PIK3CD (0.36) | ELANEHSD17B10MEN1KMT2AGPR119 | |
| SCHEMBL7163165 | 0.84 | PIK3CD (0.36) | ELANEHSD17B10MEN1KMT2AGPR119 | |
| SCHEMBL16083040 | 0.77 | HSD17B10 (0.34) | ELANEHSD17B10MEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317748-A1 | CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE | BIONOVA PHARMACEUTICALS LTD. (KY) | 2024-09-26 | — | — | US | disclosed |
| WO-2023241322-A1 | HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2023-12-21 | — | — | WO | disclosed |
| EP-4271676-A1 | CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE | Bionova Pharmaceuticals (Shanghai) Limited (CN) | 2023-11-08 | — | — | EP | disclosed |
| US-7417144-B2 | e.g. 1-Methyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-4,5-dicarboxylic acid 5-[(4-chloro-phenyl)-amide]4-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide}; anticoagulant, antiinflammatory agent; thrombosis, peripheral arterial occlusive disease, stroke, arteriosclerosis, bypass grafting | HOFFMAN-LA ROCHE INC. (US) | 2008-08-26 | — | — | US | disclosed |
| EP-1907388-A1 | NOVEL HETEROARYL FUSED CYCLIC AMINES | F. Hoffmann-Roche AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007009883-A1 | NOVEL HETEROARYL FUSED CYCLIC AMINES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-25 | — | — | WO | disclosed |
| US-20070015812-A1 | Factor Xa inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317748-A1 | CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE | SDHA, PDHA1, GLS | ELANE 2790/4885HSD17B10 1040/4885MEN1 873/4885 |
| US-20070015812-A1 | Factor Xa inhibitors | F12, F11, F2 | ELANE 77/4885HSD17B10 2368/4885MEN1 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.